CSL Behring Supports Kumamoto Earthquake Victims with Donation and Matching Gift Program

CSL Behring's Commitment to Helping Kumamoto

In light of the devastation caused by the Kumamoto earthquake in the eighth year of the Reiwa era, CSL Behring, headquartered in Minato, Tokyo, is taking significant steps to assist those affected. The company's President, Izumi Yoshida, has announced a generous donation of 1 million yen to the Japanese Red Cross Society as part of their ongoing commitment to helping communities in crisis.

In addition to this donation, CSL Behring is implementing a matching gift initiative, where the company will match the contributions made by its employees. This combined effort aims to amplify the support available for those impacted by the disaster. The funds raised will be utilized by the Japan Platform, a nonprofit organization dedicated to disaster relief efforts.

CSL Behring extends its heartfelt condolences to the victims of the earthquake, expressing hopes for the swift recovery and rehabilitation of the affected regions. The commitment of CSL Behring to corporate social responsibility is evident in its swift actions and the generous gestures made toward the communities in need.

About CSL Behring

CSL Behring is a world-renowned biotechnology company that specializes in biologic therapies. The company is dedicated to providing innovative treatments for severe and rare diseases to patients across the globe. In Japan, CSL Behring focuses on areas such as immunology, rare diseases, hereditary angioedema (HAE), hemophilia, and emergency care, ensuring that medical advancements reach those who need them most. For further information about CSL Behring and its initiatives, please visit CSL Behring Japan.

About CSL Limited

Founded in 1916, CSL Limited (ASX: CSL, USOTC: CSLLY) has established itself as a leading biotechnology company with a mission to save and improve lives through innovative medicines. The company offers a rich portfolio of life-saving products, including treatments for hemophilia, immune deficiency syndromes, influenza vaccines, iron deficiency, and renal disease. Fueled by the promise of using state-of-the-art technology to save lives, CSL now comprises three major divisions: CSL Behring, CSL Seqirus, and CSL Vifor, employing about 29,000 people worldwide and delivering vital products to patients in over 100 countries. For insights into the future of biotechnology, visit CSLBehring.com/Vita and for more comprehensive details, access CSL Limited.